Apellis Pharmaceuticals received FDA approval to broaden the labeling of its complement C3 inhibitor, Empaveli (pegcetacoplan), for treatment of complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 and older. The approval follows positive phase III Valiant study results demonstrating significant reductions in proteinuria, stabilization of kidney function, and clearance of kidney C3 deposits. Empaveli offers a novel therapeutic option for these rare and severe kidney diseases, addressing an unmet medical need. This marks Apellis's third regulatory approval in four years, underscoring its advances in complement-targeted therapies.